Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. Signal., 29 March 2011
Vol. 4, Issue 166, p. ra17
[DOI: 10.1126/scisignal.2001752]

RESEARCH ARTICLES

Editor's Summary

Driving Resistance
The promise of using targeted small-molecule kinase inhibitors in treating cancer has been shadowed by the development of resistance to these drugs. Here, Little et al. used colorectal cancer cell lines with oncogenic mutations in either KRAS or BRAF—both of which lead to increased signaling through the ERK (extracellular signal–regulated kinase) signaling pathway—to investigate the mechanisms whereby cells developed resistance to AZD6244, a MEK1/2 (mitogen-activated or extracellular signal–regulated protein kinase kinases 1 and 2) inhibitor now in clinical trials. Rather than developing mutations in MEK1/2, cancer cells became resistant to MEK1/2 through amplification of the driving oncogene (oncogenic KRAS or BRAF) and a consequent increase in signaling through the ERK pathway. These observations have implications for the use of MEK1/2 inhibitors—and possibly other inhibitors that target downstream pathway components rather than the driving oncogene itself—in combination with other antineoplastic therapies.

Citation: A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook, Amplification of the Driving Oncogene, KRAS or BRAF, Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells. Sci. Signal. 4, ra17 (2011).

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development.
A. Shilo, V. Ben Hur, P. Denichenko, I. Stein, E. Pikarsky, J. Rauch, W. Kolch, L. Zender, and R. Karni (2014)
RNA 20, 505-515
   Abstract »    Full Text »    PDF »
Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation.
C. L. Cope, R. Gilley, K. Balmanno, M. J. Sale, K. D. Howarth, M. Hampson, P. D. Smith, S. M. Guichard, and S. J. Cook (2014)
J. Cell Sci. 127, 788-800
   Abstract »    Full Text »    PDF »
Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma.
H. K. Bid, A. Kibler, D. A. Phelps, S. Manap, L. Xiao, J. Lin, D. Capper, D. Oswald, B. Geier, M. DeWire, et al. (2013)
Clin. Cancer Res. 19, 6716-6729
   Abstract »    Full Text »    PDF »
Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma.
A. Nakamura, T. Arita, S. Tsuchiya, J. Donelan, J. Chouitar, E. Carideo, K. Galvin, M. Okaniwa, T. Ishikawa, and S. Yoshida (2013)
Cancer Res. 73, 7043-7055
   Abstract »    Full Text »    PDF »
Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo.
A. Shieh, A. F. Ward, K. L. Donlan, E. R. Harding-Theobald, J. Xu, C. G. Mullighan, C. Zhang, S.-C. Chen, X. Su, J. R. Downing, et al. (2013)
Blood 121, 4884-4893
   Abstract »    Full Text »    PDF »
Kinase-Substrate Enrichment Analysis Provides Insights into the Heterogeneity of Signaling Pathway Activation in Leukemia Cells.
P. Casado, J.-C. Rodriguez-Prados, S. C. Cosulich, S. Guichard, B. Vanhaesebroeck, S. Joel, and P. R. Cutillas (2013)
Science Signaling 6, rs6
   Abstract »    Full Text »    PDF »
Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents.
M. Mao, F. Tian, J. M. Mariadason, C. C. Tsao, R. Lemos Jr, F. Dayyani, Y. N. V. Gopal, Z.-Q. Jiang, I. I. Wistuba, X. M. Tang, et al. (2013)
Clin. Cancer Res. 19, 657-667
   Abstract »    Full Text »    PDF »
Selective requirement for Mediator MED23 in Ras-active lung cancer.
X. Yang, M. Zhao, M. Xia, Y. Liu, J. Yan, H. Ji, and G. Wang (2012)
PNAS 109, E2813-E2822
   Abstract »    Full Text »    PDF »
Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance.
G. Ambrosini, C. A. Pratilas, L.-X. Qin, M. Tadi, O. Surriga, R. D. Carvajal, and G. K. Schwartz (2012)
Clin. Cancer Res. 18, 3552-3561
   Abstract »    Full Text »    PDF »
Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling.
M. Roring, R. Herr, G. J. Fiala, K. Heilmann, S. Braun, A. E. Eisenhardt, S. Halbach, D. Capper, A. von Deimling, W. W. Schamel, et al. (2012)
EMBO J. 31, 2629-2647
   Abstract »    Full Text »    PDF »
A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.
N. Deng, L. K. Goh, H. Wang, K. Das, J. Tao, I. B. Tan, S. Zhang, M. Lee, J. Wu, K. H. Lim, et al. (2012)
Gut 61, 673-684
   Abstract »    Full Text »    PDF »
ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors.
G. Hatzivassiliou, B. Liu, C. O'Brien, J. M. Spoerke, K. P. Hoeflich, P. M. Haverty, R. Soriano, W. F. Forrest, S. Heldens, H. Chen, et al. (2012)
Mol. Cancer Ther. 11, 1143-1154
   Abstract »    Full Text »    PDF »
Circumventing Cancer Drug Resistance in the Era of Personalized Medicine.
L. A. Garraway and P. A. Janne (2012)
Cancer Discovery 2, 214-226
   Abstract »    Full Text »    PDF »
ERK1/2 Regulation of CD44 Modulates Oral Cancer Aggressiveness.
N. P. Judd, A. E. Winkler, O. Murillo-Sauca, J. J. Brotman, J. H. Law, J. S. Lewis Jr, G. P. Dunn, J. D. Bui, J. B. Sunwoo, and R. Uppaluri (2012)
Cancer Res. 72, 365-374
   Abstract »    Full Text »    PDF »
Resistance to MEK Inhibitors: Should We Co-Target Upstream?.
P. I. Poulikakos and D. B. Solit (2011)
Science Signaling 4, pe16
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882